Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Anja Koschmieder"'
Autor:
Utz Krug, Anja Koschmieder, Daniela Schwammbach, Joachim Gerss, Nicola Tidow, Björn Steffen, Gesine Bug, Christian H Brandts, Markus Schaich, Christoph Röllig, Christian Thiede, Richard Noppeney, Matthias Stelljes, Thomas Büchner, Steffen Koschmieder, Ulrich Dührsen, Hubert Serve, Gerhard Ehninger, Wolfgang E Berdel, Carsten Müller-Tidow
Publikováno v:
PLoS ONE, Vol 7, Iss 12, p e52695 (2012)
Older patients with acute myeloid leukemia (AML) experience short survival despite intensive chemotherapy. Azacitidine has promising activity in patients with low proliferating AML. The aim of this dose-finding part of this trial was to evaluate feas
Externí odkaz:
https://doaj.org/article/e016895d732e4e5cabcbd393419164e8
Autor:
Utz, Krug, Christoph, Röllig, Anja, Koschmieder, Achim, Heinecke, Maria Cristina, Sauerland, Markus, Schaich, Christian, Thiede, Michael, Kramer, Jan, Braess, Karsten, Spiekermann, Torsten, Haferlach, Claudia, Haferlach, Steffen, Koschmieder, Christian, Rohde, Hubert, Serve, Bernhard, Wörmann, Wolfgang, Hiddemann, Gerhard, Ehninger, Wolfgang E, Berdel, Thomas, Büchner, Carsten, Müller-Tidow, W, Zschille
Publikováno v:
The Lancet. 376:2000-2008
Summary Background About 50% of patients (age ≥60 years) who have acute myeloid leukaemia and are otherwise medically healthy (ie, able to undergo intensive chemotherapy) achieve a complete remission (CR) after intensive chemotherapy, but with a su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5ff3cffb646bcc9129a85c5258949a6
https://doi.org/10.1016/s0140-6736(10)62105-8
https://doi.org/10.1016/s0140-6736(10)62105-8
Autor:
Gerhard Ehninger, Mathias Hänel, Martin Kaufmann, Steffen Koschmieder, Roland Repp, Claudia D. Baldus, Ulrich Kaiser, Joachim Gerss, Christoph Röllig, Wolfgang E. Berdel, Tim H. Brümmendorf, Ralph Naumann, Hartmut Link, Hubert Serve, Martin Görner, Andreas Neubauer, Lilly Meredith, Stefanie Goellner, Björn Steffen, Trude Butterfaß-Bahloul, Martin Dugas, Haack Bea, Richard Noppeney, Carsten Müller-Tidow, Ruth Wagner, Albrecht Reichle, Petra Tschanter, Kerstin Schäfer-Eckart, Aristoteles Giagounidis, Utz Krug, Volker Kunzmann, Norbert Schmitz, Stefan W. Krause, Michael G. Kiehl, Wolfgang Herr, Anja Koschmieder, Rudolf Peceny, Katharina Götze, Norbert Frickhofen, Christian Thiede, Alexander Kiani
Publikováno v:
Blood. 124:946-946
Introduction Aberrant DNA methylation is a common feature of acute myeloid leukemia (AML) and increases with age. DNMT inhibitors such as Azacitidine (AZA) can induce meaningful responses and remissions in AML as monotherapy. The combination of AZA w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::534b70e1a45828061d031ced94ea7119
https://doi.org/10.1182/blood.v124.21.946.946
https://doi.org/10.1182/blood.v124.21.946.946
Autor:
Wolfgang Hiddemann, Achim Heinecke, Carsten Müller-Tidow, Maria Cristina Sauerland, Jan Braess, Wolfgang E. Berdel, Thomas Büchner, Anja Koschmieder, Claudia Haferlach, Utz Krug, Torsten Haferlach, Karsten Spiekermann, Gerhard Ehninger, Bernhard J. Woermann, Christoph Röllig, Christian Rohde, Michael Kramer, Christian Thiede, Markus Schaich
Publikováno v:
Blood. 116:2696-2696
Abstract 2696 Introduction: The prognosis of older patients (≥ 60 years) with acute myeloid leukemia (AML) is generally poor. The decision whether or not to use intensive chemotherapy in this patient cohort is challenging since only half of all old
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eadff950ba33aaa5132e948992627ef4
https://doi.org/10.1182/blood.v116.21.2696.2696
https://doi.org/10.1182/blood.v116.21.2696.2696
Autor:
Utz Krug, Matthias Stelljes, Achim Heinecke, Bernhard J. Woermann, Wolfgang E. Berdel, Maria Cristina Sauerland, Wolfgang Hiddemann, Thomas Büchner, Anja Koschmieder, Carsten Müller-Tidow
Publikováno v:
Blood. 114:327-327
Abstract 327 Introduction: Older patients (≥ 60 years) with acute myeloid leukemia (AML) display a dismal prognosis with only half of the patients reaching a complete remission after intensive induction therapy. The decision whether or not to use i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f8687aaf5be74568a408ecc9d41a86be
https://doi.org/10.1182/blood.v114.22.327.327
https://doi.org/10.1182/blood.v114.22.327.327